CA2965973A1

CA2965973A1 - Pif binding as a marker for immune dysregulation

Pif binding as a marker for immune dysregulation Download PDF

Info

Publication number: CA2965973A1
Authority: CA; Canada
Prior art keywords: seq; pif; cells; analog; immune
Prior art date: 2014-11-03
Legal status : Abandoned

Application number

CA2965973A

Other languages

English (en)

French (fr)

Inventor

Eytan R. Barnea

Current Assignee

BioIncept LLC

Original Assignee

BioIncept LLC

Priority date

2014-11-03

Filing date

2015-11-03

Publication date

2016-05-12

2015-09-16 Priority claimed from PCT/US2015/050532 external-priority patent/WO2016044493A1/en

2015-11-03 Application filed by BioIncept LLC filed Critical BioIncept LLC

2016-05-12 Publication of CA2965973A1 publication Critical patent/CA2965973A1/en

Status Abandoned legal-status Critical Current

Links

230000027455 binding Effects 0.000 title claims abstract description 314
230000008938 immune dysregulation Effects 0.000 title claims abstract description 184
239000003550 marker Substances 0.000 title abstract description 12
210000002865 immune cell Anatomy 0.000 claims abstract description 347
238000000034 method Methods 0.000 claims abstract description 210
GLXYOFXNKBTMQL-YKCHQESGSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)CCC1 GLXYOFXNKBTMQL-YKCHQESGSA-N 0.000 claims abstract description 175
201000009273 Endometriosis Diseases 0.000 claims abstract description 76
230000008859 change Effects 0.000 claims abstract description 59
206010055690 Foetal death Diseases 0.000 claims abstract description 22
230000000306 recurrent effect Effects 0.000 claims abstract description 17
210000004027 cell Anatomy 0.000 claims description 277
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 89
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 88
210000004443 dendritic cell Anatomy 0.000 claims description 76
210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 67
239000007787 solid Substances 0.000 claims description 63
-1 PIF amino acid Chemical class 0.000 claims description 61
102000004127 Cytokines Human genes 0.000 claims description 35
108090000695 Cytokines Proteins 0.000 claims description 35
238000000684 flow cytometry Methods 0.000 claims description 29
230000014509 gene expression Effects 0.000 claims description 27
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 25
102000004899 14-3-3 Proteins Human genes 0.000 claims description 24
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 22
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 22
230000007423 decrease Effects 0.000 claims description 17
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
102100038938 Myosin-9 Human genes 0.000 claims description 13
210000004369 blood Anatomy 0.000 claims description 12
239000008280 blood Substances 0.000 claims description 12
230000009467 reduction Effects 0.000 claims description 12
101710204108 Myosin-9 Proteins 0.000 claims description 11
230000003100 immobilizing effect Effects 0.000 claims description 9
239000002955 immunomodulating agent Substances 0.000 claims description 8
101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 claims description 5
239000000377 silicon dioxide Substances 0.000 claims description 5
230000006916 protein interaction Effects 0.000 claims description 4
208000026278 immune system disease Diseases 0.000 abstract description 15
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 280
239000012634 fragment Substances 0.000 description 192
108090000765 processed proteins & peptides Proteins 0.000 description 153
108090000623 proteins and genes Proteins 0.000 description 151
102000004169 proteins and genes Human genes 0.000 description 135
235000018102 proteins Nutrition 0.000 description 126
239000000523 sample Substances 0.000 description 106
102000004196 processed proteins & peptides Human genes 0.000 description 88
150000001875 compounds Chemical class 0.000 description 78
239000000203 mixture Substances 0.000 description 75
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 61
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 60
229920001184 polypeptide Polymers 0.000 description 58
229940024606 amino acid Drugs 0.000 description 57
235000001014 amino acid Nutrition 0.000 description 57
150000001413 amino acids Chemical class 0.000 description 55
150000003839 salts Chemical class 0.000 description 43
230000000694 effects Effects 0.000 description 42
108010022347 proteolysis-inducing peptide Proteins 0.000 description 34
239000000243 solution Substances 0.000 description 34
108010047620 Phytohemagglutinins Proteins 0.000 description 32
230000001885 phytohemagglutinin Effects 0.000 description 32
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 31
125000003275 alpha amino acid group Chemical group 0.000 description 30
230000035935 pregnancy Effects 0.000 description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
239000002158 endotoxin Substances 0.000 description 24
230000003993 interaction Effects 0.000 description 24
229920006008 lipopolysaccharide Polymers 0.000 description 24
239000008194 pharmaceutical composition Substances 0.000 description 24
238000004458 analytical method Methods 0.000 description 23
239000000306 component Substances 0.000 description 23
230000006870 function Effects 0.000 description 21
239000000463 material Substances 0.000 description 21
238000009472 formulation Methods 0.000 description 20
210000002540 macrophage Anatomy 0.000 description 19
108010029485 Protein Isoforms Proteins 0.000 description 18
102000001708 Protein Isoforms Human genes 0.000 description 18
238000002474 experimental method Methods 0.000 description 17
239000000816 peptidomimetic Substances 0.000 description 17
230000001225 therapeutic effect Effects 0.000 description 17
230000004913 activation Effects 0.000 description 16
210000001519 tissue Anatomy 0.000 description 16
238000001042 affinity chromatography Methods 0.000 description 14
238000001514 detection method Methods 0.000 description 14
230000001965 increasing effect Effects 0.000 description 14
210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 14
230000003247 decreasing effect Effects 0.000 description 13
201000010099 disease Diseases 0.000 description 13
208000035475 disorder Diseases 0.000 description 13
239000011159 matrix material Substances 0.000 description 13
239000012528 membrane Substances 0.000 description 13
210000004379 membrane Anatomy 0.000 description 13
239000000126 substance Substances 0.000 description 13
238000006467 substitution reaction Methods 0.000 description 13
210000001744 T-lymphocyte Anatomy 0.000 description 12
239000002253 acid Substances 0.000 description 12
239000003446 ligand Substances 0.000 description 12
210000001616 monocyte Anatomy 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
102100035071 Vimentin Human genes 0.000 description 11
108010065472 Vimentin Proteins 0.000 description 11
239000000872 buffer Substances 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
239000003937 drug carrier Substances 0.000 description 11
238000000605 extraction Methods 0.000 description 11
210000000987 immune system Anatomy 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
239000013074 reference sample Substances 0.000 description 11
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
238000011282 treatment Methods 0.000 description 11
210000005048 vimentin Anatomy 0.000 description 11
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
101710117490 Circumsporozoite protein Proteins 0.000 description 10
101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 10
108090000174 Interleukin-10 Proteins 0.000 description 10
102000003814 Interleukin-10 Human genes 0.000 description 10
108090000978 Interleukin-4 Proteins 0.000 description 10
108010078233 Thymalfasin Proteins 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
230000036039 immunity Effects 0.000 description 10
201000004792 malaria Diseases 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 10
229960004231 thymalfasin Drugs 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
102000000584 Calmodulin Human genes 0.000 description 9
108010041952 Calmodulin Proteins 0.000 description 9
241000282412 Homo Species 0.000 description 9
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 9
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 9
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
102400000800 Thymosin alpha-1 Human genes 0.000 description 9
239000004480 active ingredient Substances 0.000 description 9
150000001408 amides Chemical class 0.000 description 9
239000000427 antigen Substances 0.000 description 9
230000028993 immune response Effects 0.000 description 9
230000008774 maternal effect Effects 0.000 description 9
210000000440 neutrophil Anatomy 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
210000003289 regulatory T cell Anatomy 0.000 description 9
230000004044 response Effects 0.000 description 9
239000000758 substrate Substances 0.000 description 9
239000004475 Arginine Substances 0.000 description 8
108010010803 Gelatin Proteins 0.000 description 8
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 8
239000004698 Polyethylene Substances 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
229920002472 Starch Polymers 0.000 description 8
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 8
210000003719 b-lymphocyte Anatomy 0.000 description 8
239000002775 capsule Substances 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
239000008273 gelatin Substances 0.000 description 8
229920000159 gelatin Polymers 0.000 description 8
235000019322 gelatine Nutrition 0.000 description 8
235000011852 gelatine desserts Nutrition 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
239000002609 medium Substances 0.000 description 8
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
210000005259 peripheral blood Anatomy 0.000 description 8
239000011886 peripheral blood Substances 0.000 description 8
229920001343 polytetrafluoroethylene Polymers 0.000 description 8
239000004810 polytetrafluoroethylene Substances 0.000 description 8
230000008569 process Effects 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
239000002904 solvent Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
108010085238 Actins Proteins 0.000 description 7
102000007469 Actins Human genes 0.000 description 7
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 7
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 7
241000124008 Mammalia Species 0.000 description 7
102100039360 Toll-like receptor 4 Human genes 0.000 description 7
102000005937 Tropomyosin Human genes 0.000 description 7
108010030743 Tropomyosin Proteins 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 7
210000000612 antigen-presenting cell Anatomy 0.000 description 7
238000003491 array Methods 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000012545 processing Methods 0.000 description 7
239000011347 resin Substances 0.000 description 7
229920005989 resin Polymers 0.000 description 7
230000028327 secretion Effects 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
238000005406 washing Methods 0.000 description 7
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
108700012920 TNF Proteins 0.000 description 6
102100036977 Talin-1 Human genes 0.000 description 6
239000012472 biological sample Substances 0.000 description 6
230000003915 cell function Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000011161 development Methods 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
239000011521 glass Substances 0.000 description 6
230000002519 immonomodulatory effect Effects 0.000 description 6
230000005934 immune activation Effects 0.000 description 6
230000006058 immune tolerance Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000008101 lactose Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000006166 lysate Substances 0.000 description 6
230000002934 lysing effect Effects 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
210000001161 mammalian embryo Anatomy 0.000 description 6
230000036542 oxidative stress Effects 0.000 description 6
239000012071 phase Substances 0.000 description 6
239000006187 pill Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 5
101710183121 14-3-3 protein zeta/delta Proteins 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
102100029968 Calreticulin Human genes 0.000 description 5
102100032231 Caveolae-associated protein 2 Human genes 0.000 description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
239000004793 Polystyrene Substances 0.000 description 5
101710142287 Talin-1 Proteins 0.000 description 5
102100036407 Thioredoxin Human genes 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
239000013543 active substance Substances 0.000 description 5
230000006907 apoptotic process Effects 0.000 description 5
125000004429 atom Chemical group 0.000 description 5
230000008827 biological function Effects 0.000 description 5
238000001574 biopsy Methods 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 5
229920002678 cellulose Polymers 0.000 description 5
239000001913 cellulose Substances 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
210000004292 cytoskeleton Anatomy 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
239000004205 dimethyl polysiloxane Substances 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
210000000265 leukocyte Anatomy 0.000 description 5
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 5
238000004949 mass spectrometry Methods 0.000 description 5
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
210000000822 natural killer cell Anatomy 0.000 description 5
239000013642 negative control Substances 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
108010044762 nucleolin Proteins 0.000 description 5
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
229920002223 polystyrene Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000010356 sorbitol Nutrition 0.000 description 5
239000000600 sorbitol Substances 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
230000008685 targeting Effects 0.000 description 5
230000003614 tolerogenic effect Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
108700020469 14-3-3 Proteins 0.000 description 4
101710112812 14-3-3 protein Proteins 0.000 description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
102000014914 Carrier Proteins Human genes 0.000 description 4
102000004360 Cofilin 1 Human genes 0.000 description 4
108090000996 Cofilin 1 Proteins 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
229920002307 Dextran Polymers 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
241000283073 Equus caballus Species 0.000 description 4
230000005526 G1 to G0 transition Effects 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
108010004889 Heat-Shock Proteins Proteins 0.000 description 4
102000002812 Heat-Shock Proteins Human genes 0.000 description 4
102100034523 Histone H4 Human genes 0.000 description 4
108010033040 Histones Proteins 0.000 description 4
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
102100027105 Lymphocyte-specific protein 1 Human genes 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
AXDLCFOOGCNDST-UHFFFAOYSA-N N-Methyltyrosine Chemical compound CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 4
KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 4
102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 4
101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 4
102100021010 Nucleolin Human genes 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
239000004743 Polypropylene Substances 0.000 description 4
102100037044 Serine/arginine-rich splicing factor 1 Human genes 0.000 description 4
102000007562 Serum Albumin Human genes 0.000 description 4
108010071390 Serum Albumin Proteins 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
102100024944 Tropomyosin alpha-4 chain Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
102100028985 Tubulin alpha-1C chain Human genes 0.000 description 4
230000009471 action Effects 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
239000002585 base Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
108091008324 binding proteins Proteins 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
239000004202 carbamide Substances 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
230000035605 chemotaxis Effects 0.000 description 4
125000004122 cyclic group Chemical group 0.000 description 4
239000003599 detergent Substances 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
230000029087 digestion Effects 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000008298 dragée Substances 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
210000001808 exosome Anatomy 0.000 description 4
239000000284 extract Substances 0.000 description 4
210000003608 fece Anatomy 0.000 description 4
210000003754 fetus Anatomy 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
210000003630 histaminocyte Anatomy 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000002513 implantation Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
239000004417 polycarbonate Substances 0.000 description 4
229920000515 polycarbonate Polymers 0.000 description 4
229920000139 polyethylene terephthalate Polymers 0.000 description 4
239000005020 polyethylene terephthalate Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000004926 polymethyl methacrylate Substances 0.000 description 4
229920001155 polypropylene Polymers 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
150000004492 retinoid derivatives Chemical class 0.000 description 4
239000012488 sample solution Substances 0.000 description 4
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
238000000926 separation method Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
208000000995 spontaneous abortion Diseases 0.000 description 4
238000007619 statistical method Methods 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
108060008226 thioredoxin Proteins 0.000 description 4
229940094937 thioredoxin Drugs 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
101710188276 14-3-3 protein eta Proteins 0.000 description 3
102100024682 14-3-3 protein eta Human genes 0.000 description 3
102100027832 14-3-3 protein gamma Human genes 0.000 description 3
101710191812 14-3-3 protein gamma Proteins 0.000 description 3
101710108995 14-3-3 protein theta Proteins 0.000 description 3
102100027831 14-3-3 protein theta Human genes 0.000 description 3
TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102100022997 Acidic leucine-rich nuclear phosphoprotein 32 family member A Human genes 0.000 description 3
101710170757 Acidic leucine-rich nuclear phosphoprotein 32 family member A Proteins 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
108091008875 B cell receptors Proteins 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 3
108090000549 Calreticulin Proteins 0.000 description 3
108050005259 Caveolae-associated protein 2 Proteins 0.000 description 3
230000005778 DNA damage Effects 0.000 description 3
231100000277 DNA damage Toxicity 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
241000283086 Equidae Species 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
108010072051 Glatiramer Acetate Proteins 0.000 description 3
102000006354 HLA-DR Antigens Human genes 0.000 description 3
108010058597 HLA-DR Antigens Proteins 0.000 description 3
102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
102000004195 Isomerases Human genes 0.000 description 3
108090000769 Isomerases Proteins 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 3
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 3
239000004952 Polyamide Substances 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102100032442 Protein S100-A8 Human genes 0.000 description 3
102100027171 Protein SET Human genes 0.000 description 3
101710148582 Protein SET Proteins 0.000 description 3
230000004570 RNA-binding Effects 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
101710123510 Serine/arginine-rich splicing factor 1 Proteins 0.000 description 3
230000006044 T cell activation Effects 0.000 description 3
108091008874 T cell receptors Proteins 0.000 description 3
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
108010046722 Thrombospondin 1 Proteins 0.000 description 3
102100036034 Thrombospondin-1 Human genes 0.000 description 3
102000002689 Toll-like receptor Human genes 0.000 description 3
108020000411 Toll-like receptor Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
101710193115 Tropomyosin alpha-4 chain Proteins 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000008272 agar Substances 0.000 description 3
235000010419 agar Nutrition 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
235000012538 ammonium bicarbonate Nutrition 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000007621 cluster analysis Methods 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
238000012258 culturing Methods 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
229960002433 cysteine Drugs 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
210000003785 decidua Anatomy 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
210000002751 lymph Anatomy 0.000 description 3
108010040838 lymphocyte-specific protein p50 Proteins 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
230000004879 molecular function Effects 0.000 description 3
GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 3
238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000000123 paper Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000037361 pathway Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
210000002826 placenta Anatomy 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
230000010118 platelet activation Effects 0.000 description 3
230000018127 platelet degranulation Effects 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
229920002647 polyamide Polymers 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
239000004800 polyvinyl chloride Substances 0.000 description 3
229920000915 polyvinyl chloride Polymers 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
238000011002 quantification Methods 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
230000035939 shock Effects 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
238000004885 tandem mass spectrometry Methods 0.000 description 3
102000004217 thyroid hormone receptors Human genes 0.000 description 3
108090000721 thyroid hormone receptors Proteins 0.000 description 3
230000003827 upregulation Effects 0.000 description 3
229920002554 vinyl polymer Polymers 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 2
XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 2
CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 2
PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 2
102100021408 14-3-3 protein beta/alpha Human genes 0.000 description 2
101710161661 14-3-3 protein beta/alpha Proteins 0.000 description 2
102100025007 14-3-3 protein epsilon Human genes 0.000 description 2
101710125124 14-3-3 protein epsilon Proteins 0.000 description 2
102000021233 14-3-3 theta Human genes 0.000 description 2
108091011161 14-3-3 theta Proteins 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
KWWFNGCKGYUCLC-UHFFFAOYSA-N 3,3-dimethyl-2-(methylamino)butanoic acid Chemical compound CNC(C(O)=O)C(C)(C)C KWWFNGCKGYUCLC-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
208000001395 Acute radiation syndrome Diseases 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102100034163 Alpha-actinin-1 Human genes 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
102000000412 Annexin Human genes 0.000 description 2
108050008874 Annexin Proteins 0.000 description 2
229940088872 Apoptosis inhibitor Drugs 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
101710113502 Branchpoint-bridging protein Proteins 0.000 description 2
102000050091 Bridging integrator 2 Human genes 0.000 description 2
108700039178 Bridging integrator 2 Proteins 0.000 description 2
239000004322 Butylated hydroxytoluene Substances 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
108050003114 Coronin 1A Proteins 0.000 description 2
102100028233 Coronin-1A Human genes 0.000 description 2
102000001189 Cyclic Peptides Human genes 0.000 description 2
108010069514 Cyclic Peptides Proteins 0.000 description 2
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
102100039328 Endoplasmin Human genes 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
102000013366 Filamin Human genes 0.000 description 2
108060002900 Filamin Proteins 0.000 description 2
102000004878 Gelsolin Human genes 0.000 description 2
108090001064 Gelsolin Proteins 0.000 description 2
208000007465 Giant cell arteritis Diseases 0.000 description 2
102100021223 Glucosidase 2 subunit beta Human genes 0.000 description 2
108050000822 Glucosidase 2 subunit beta Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
208000008899 Habitual abortion Diseases 0.000 description 2
102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 2
102300042222 Heat shock protein HSP 90-alpha isoform 2 Human genes 0.000 description 2
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
102100023584 Histone-binding protein RBBP7 Human genes 0.000 description 2
101000723517 Homo sapiens 14-3-3 protein gamma Proteins 0.000 description 2
101000799406 Homo sapiens Alpha-actinin-1 Proteins 0.000 description 2
101000793651 Homo sapiens Calreticulin Proteins 0.000 description 2
101000869050 Homo sapiens Caveolae-associated protein 2 Proteins 0.000 description 2
101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 2
101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 2
101001030232 Homo sapiens Myosin-9 Proteins 0.000 description 2
101000838350 Homo sapiens Tubulin alpha-1C chain Proteins 0.000 description 2
102100028627 Hornerin Human genes 0.000 description 2
101710100096 Hornerin Proteins 0.000 description 2
108010058683 Immobilized Proteins Proteins 0.000 description 2
102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
108010005716 Interferon beta-1a Proteins 0.000 description 2
108010005714 Interferon beta-1b Proteins 0.000 description 2
108090000467 Interferon-beta Proteins 0.000 description 2
102000003996 Interferon-beta Human genes 0.000 description 2
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 2
208000035752 Live birth Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
102100038645 Matrin-3 Human genes 0.000 description 2
101710146614 Matrin-3 Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
102000002151 Microfilament Proteins Human genes 0.000 description 2
108010040897 Microfilament Proteins Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 2
SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 2
GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 2
XLBVNMSMFQMKEY-BYPYZUCNSA-N N-methyl-L-glutamic acid Chemical compound CN[C@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-BYPYZUCNSA-N 0.000 description 2
SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 2
CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
206010034277 Pemphigoid Diseases 0.000 description 2
101710171421 Phosphoprotein 32 Proteins 0.000 description 2
102100035182 Plastin-2 Human genes 0.000 description 2
101710081231 Plastin-2 Proteins 0.000 description 2
229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
229920001665 Poly-4-vinylphenol Polymers 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
101710156987 Protein S100-A8 Proteins 0.000 description 2
102100037089 Protein disulfide-isomerase A4 Human genes 0.000 description 2
101710106226 Protein disulfide-isomerase A4 Proteins 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
206010068142 Radiation sickness syndrome Diseases 0.000 description 2
102100030800 Ras suppressor protein 1 Human genes 0.000 description 2
108010077895 Sarcosine Proteins 0.000 description 2
102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 description 2
101710123513 Serine/arginine-rich splicing factor 2 Proteins 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
102000004584 Somatomedin Receptors Human genes 0.000 description 2
108010017622 Somatomedin Receptors Proteins 0.000 description 2
101710153291 Splicing factor 1 Proteins 0.000 description 2
102100030056 Splicing factor 1 Human genes 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
102100029219 Thrombospondin-4 Human genes 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
102000003672 Tropomodulin Human genes 0.000 description 2
108090000089 Tropomodulin Proteins 0.000 description 2
102100035287 Tropomodulin-3 Human genes 0.000 description 2
101710106373 Tubulin alpha-1C chain Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
108010048626 Y-Box-Binding Protein 1 Proteins 0.000 description 2
102100022224 Y-box-binding protein 1 Human genes 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000003044 adaptive effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000000158 apoptosis inhibitor Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
229940095259 butylated hydroxytoluene Drugs 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000021523 carboxylation Effects 0.000 description 2
238000006473 carboxylation reaction Methods 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
230000009087 cell motility Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
230000004637 cellular stress Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
230000006690 co-activation Effects 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229940035811 conjugated estrogen Drugs 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
229950006137 dexfosfoserine Drugs 0.000 description 2
LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
108010011867 ecallantide Proteins 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
210000005168 endometrial cell Anatomy 0.000 description 2
108010022937 endoplasmin Proteins 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
239000005038 ethylene vinyl acetate Substances 0.000 description 2
230000005284 excitation Effects 0.000 description 2
KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
229960000556 fingolimod Drugs 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
229940042385 glatiramer Drugs 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000004153 glucose metabolism Effects 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
108010052188 hepatoma-derived growth factor Proteins 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229960001388 interferon-beta Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000029226 lipidation Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
229960001428 mercaptopurine Drugs 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
229960003753 nitric oxide Drugs 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
GHLZUHZBBNDWHW-UHFFFAOYSA-N nonanamide Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000003076 paracrine Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000002304 perfume Substances 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 2
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
229920002492 poly(sulfone) Polymers 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
229920000098 polyolefin Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000000861 pro-apoptotic effect Effects 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
108020003519 protein disulfide isomerase Proteins 0.000 description 2
239000000018 receptor agonist Substances 0.000 description 2
229940044601 receptor agonist Drugs 0.000 description 2
230000016914 response to endoplasmic reticulum stress Effects 0.000 description 2
230000003938 response to stress Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
239000012146 running buffer Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
229940043230 sarcosine Drugs 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000003393 splenic effect Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
206010043207 temporal arteritis Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
108010060815 thrombospondin 4 Proteins 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
238000010798 ubiquitination Methods 0.000 description 2
230000034512 ubiquitination Effects 0.000 description 2
230000004906 unfolded protein response Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
OSBJZDSTRAMDPL-VIFPVBQESA-N (2s)-2-(methylamino)-3-(1h-pyrrolo[2,3-b]pyridin-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](NC)C(O)=O)=CNC2=N1 OSBJZDSTRAMDPL-VIFPVBQESA-N 0.000 description 1
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
SNLOIIPRZGMRAB-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(1h-pyrrolo[2,3-b]pyridin-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H]([NH3+])C([O-])=O)=CNC2=N1 SNLOIIPRZGMRAB-QMMMGPOBSA-N 0.000 description 1
IUAXSWPNEQYKDR-GXTZACRKSA-N (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one 2,3-dihydroxybutanedioic acid dihydrate Chemical compound O.O.OC(C(O)C(O)=O)C(O)=O.COc1ccc2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5Oc1c2[C@]45CCN3C IUAXSWPNEQYKDR-GXTZACRKSA-N 0.000 description 1
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
125000006582 (C5-C6) heterocycloalkyl group Chemical class 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 1
WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
HGIPIEYZJPULIQ-UHFFFAOYSA-N 2-(methylazaniumyl)-2-phenylacetate Chemical compound CNC(C(O)=O)C1=CC=CC=C1 HGIPIEYZJPULIQ-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 1
JINGUCXQUOKWKH-UHFFFAOYSA-N 2-aminodecanoic acid Chemical compound CCCCCCCCC(N)C(O)=O JINGUCXQUOKWKH-UHFFFAOYSA-N 0.000 description 1
QUBNFZFTFXTLKH-UHFFFAOYSA-N 2-aminododecanoic acid Chemical compound CCCCCCCCCCC(N)C(O)=O QUBNFZFTFXTLKH-UHFFFAOYSA-N 0.000 description 1
LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
HASUJDLTAYUWCO-UHFFFAOYSA-N 2-aminoundecanoic acid Chemical compound CCCCCCCCCC(N)C(O)=O HASUJDLTAYUWCO-UHFFFAOYSA-N 0.000 description 1
JVPFOKXICYJJSC-UHFFFAOYSA-N 2-azaniumylnonanoate Chemical compound CCCCCCCC(N)C(O)=O JVPFOKXICYJJSC-UHFFFAOYSA-N 0.000 description 1
AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
VTZPAJGVRWKMAG-UHFFFAOYSA-N 3-(1h-imidazol-5-ylmethyl)-2,3-dihydro-1h-inden-5-ol Chemical compound C12=CC(O)=CC=C2CCC1CC1=CN=CN1 VTZPAJGVRWKMAG-UHFFFAOYSA-N 0.000 description 1
RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 1
DPDPQQHHTHKSRN-UHFFFAOYSA-N 4-aminooxane-4-carboxylic acid Chemical compound OC(=O)C1(N)CCOCC1 DPDPQQHHTHKSRN-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
102100037685 60S ribosomal protein L22 Human genes 0.000 description 1
101710187788 60S ribosomal protein L22 Proteins 0.000 description 1
125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
101710143116 Actin, cytoplasmic Proteins 0.000 description 1
102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
101710119043 Actin, cytoplasmic 1 Proteins 0.000 description 1
102100030374 Actin, cytoplasmic 2 Human genes 0.000 description 1
101710119042 Actin, cytoplasmic 2 Proteins 0.000 description 1
101710197633 Actin-1 Proteins 0.000 description 1
102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 1
101710111216 Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
102300042785 Adenylyl cyclase-associated protein 1 isoform 2 Human genes 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
208000008190 Agammaglobulinemia Diseases 0.000 description 1
ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
GNRLUBOJIGSVNT-UHFFFAOYSA-N Aminoethoxyacetic acid Chemical compound NCCOCC(O)=O GNRLUBOJIGSVNT-UHFFFAOYSA-N 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
102100040199 Apolipoprotein B receptor Human genes 0.000 description 1
101000834552 Arabidopsis thaliana Alpha-glucosidase 2 Proteins 0.000 description 1
GFMWTFHOZGLTLC-AVGNSLFASA-N Arg-His-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(O)=O GFMWTFHOZGLTLC-AVGNSLFASA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
IIFDPDVJAHQFSR-WHFBIAKZSA-N Asn-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O IIFDPDVJAHQFSR-WHFBIAKZSA-N 0.000 description 1
JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 1
208000030767 Autoimmune encephalitis Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
210000003771 C cell Anatomy 0.000 description 1
108090000342 C-Type Lectins Proteins 0.000 description 1
102000003930 C-Type Lectins Human genes 0.000 description 1
102100026197 C-type lectin domain family 2 member D Human genes 0.000 description 1
101710112307 CEP120 Proteins 0.000 description 1
201000002829 CREST Syndrome Diseases 0.000 description 1
102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 1
102100023304 Centrosomal protein of 120 kDa Human genes 0.000 description 1
GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
101710163595 Chaperone protein DnaK Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
102000008169 Co-Repressor Proteins Human genes 0.000 description 1
108010060434 Co-Repressor Proteins Proteins 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
208000011038 Cold agglutinin disease Diseases 0.000 description 1
206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
108010069112 Complement System Proteins Proteins 0.000 description 1
102000000989 Complement System Proteins Human genes 0.000 description 1
108010002947 Connectin Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
101710095468 Cyclase Proteins 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 1
AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
101100102624 Drosophila melanogaster Vinc gene Proteins 0.000 description 1
102100021238 Dynamin-2 Human genes 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
241000792859 Enema Species 0.000 description 1
229940122601 Esterase inhibitor Drugs 0.000 description 1
RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
241000282324 Felis Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
SSHIXEILTLPAQT-WHFBIAKZSA-N Gln-Asp Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSHIXEILTLPAQT-WHFBIAKZSA-N 0.000 description 1
PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 description 1
JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
108010024164 HLA-G Antigens Proteins 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
101710113864 Heat shock protein 90 Proteins 0.000 description 1
101710147599 Heat shock protein HSP 90-alpha Proteins 0.000 description 1
101710163596 Heat shock protein HSP 90-beta Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102300055586 Hepatoma-derived growth factor isoform 2 Human genes 0.000 description 1
102000017286 Histone H2A Human genes 0.000 description 1
108050005231 Histone H2A Proteins 0.000 description 1
101710104855 Histone H2A type 1-B/E Proteins 0.000 description 1
102100039266 Histone H2A type 1-B/E Human genes 0.000 description 1
102100022823 Histone RNA hairpin-binding protein Human genes 0.000 description 1
101710181536 Histone-binding protein RBBP7 Proteins 0.000 description 1
101000773237 Homo sapiens Actin, cytoplasmic 2 Proteins 0.000 description 1
101000912615 Homo sapiens C-type lectin domain family 2 member D Proteins 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101000993339 Homo sapiens Centlein Proteins 0.000 description 1
101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
101001078626 Homo sapiens Heat shock protein HSP 90-alpha A2 Proteins 0.000 description 1
101000825762 Homo sapiens Histone RNA hairpin-binding protein Proteins 0.000 description 1
101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
101000984710 Homo sapiens Lymphocyte-specific protein 1 Proteins 0.000 description 1
101000624625 Homo sapiens M-phase inducer phosphatase 1 Proteins 0.000 description 1
101001099460 Homo sapiens Myeloperoxidase Proteins 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
101001072191 Homo sapiens Protein disulfide-isomerase A2 Proteins 0.000 description 1
101000636109 Homo sapiens Ras suppressor protein 1 Proteins 0.000 description 1
101000663222 Homo sapiens Serine/arginine-rich splicing factor 1 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
101000598025 Homo sapiens Talin-1 Proteins 0.000 description 1
101001090050 Homo sapiens Thioredoxin-dependent peroxide reductase, mitochondrial Proteins 0.000 description 1
101000597778 Homo sapiens Tropomodulin-3 Proteins 0.000 description 1
101000830781 Homo sapiens Tropomyosin alpha-4 chain Proteins 0.000 description 1
101000788548 Homo sapiens Tubulin alpha-4A chain Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
208000010159 IgA glomerulonephritis Diseases 0.000 description 1
206010021263 IgA nephropathy Diseases 0.000 description 1
FCWFBHMAJZGWRY-XUXIUFHCSA-N Ile-Leu-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N FCWFBHMAJZGWRY-XUXIUFHCSA-N 0.000 description 1
ZSESFIFAYQEKRD-CYDGBPFRSA-N Ile-Val-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N ZSESFIFAYQEKRD-CYDGBPFRSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100033461 Interleukin-17A Human genes 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
102100027000 Latent-transforming growth factor beta-binding protein 1 Human genes 0.000 description 1
101710178954 Latent-transforming growth factor beta-binding protein 1 Proteins 0.000 description 1
101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
241000880493 Leptailurus serval Species 0.000 description 1
HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
JKSIBWITFMQTOA-XUXIUFHCSA-N Leu-Ile-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O JKSIBWITFMQTOA-XUXIUFHCSA-N 0.000 description 1
QQXJROOJCMIHIV-AVGNSLFASA-N Leu-Val-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O QQXJROOJCMIHIV-AVGNSLFASA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102300059455 Leucine-rich repeat flightless-interacting protein 1 isoform 2 Human genes 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 1
SQJSXOQXJYAVRV-SRVKXCTJSA-N Lys-His-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N SQJSXOQXJYAVRV-SRVKXCTJSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102100023326 M-phase inducer phosphatase 1 Human genes 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
208000027530 Meniere disease Diseases 0.000 description 1
WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
208000003250 Mixed connective tissue disease Diseases 0.000 description 1
229930191564 Monensin Natural products 0.000 description 1
GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
102100027994 Myeloid cell nuclear differentiation antigen Human genes 0.000 description 1
101710141650 Myeloid cell nuclear differentiation antigen Proteins 0.000 description 1
102000003896 Myeloperoxidases Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
PQNASZJZHFPQLE-UHFFFAOYSA-N N(6)-methyllysine Chemical compound CNCCCCC(N)C(O)=O PQNASZJZHFPQLE-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
YAXAFCHJCYILRU-YFKPBYRVSA-N N-methyl-L-methionine Chemical compound C[NH2+][C@H](C([O-])=O)CCSC YAXAFCHJCYILRU-YFKPBYRVSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
102100023904 Nuclear autoantigenic sperm protein Human genes 0.000 description 1
101710149564 Nuclear autoantigenic sperm protein Proteins 0.000 description 1
102100021007 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 Human genes 0.000 description 1
101710165860 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
102300036810 Nucleophosmin isoform 2 Human genes 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000000450 Pelvic Pain Diseases 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
102000007456 Peroxiredoxin Human genes 0.000 description 1
240000000697 Pinguicula vulgaris Species 0.000 description 1
102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
102100030582 Platelet factor 4 variant Human genes 0.000 description 1
101710198959 Platelet factor 4 variant Proteins 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100036351 Protein disulfide-isomerase A2 Human genes 0.000 description 1
108010026552 Proteome Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
102100034419 Ras GTPase-activating-like protein IQGAP1 Human genes 0.000 description 1
101710145390 Ras GTPase-activating-like protein IQGAP1 Proteins 0.000 description 1
101710102668 Ras suppressor protein 1 Proteins 0.000 description 1
101000981468 Rattus norvegicus Parkinson disease protein 7 homolog Proteins 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
108010071000 Retinoblastoma-Binding Protein 7 Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
SZRNDHWMVSFPSP-XKBZYTNZSA-N Ser-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N)O SZRNDHWMVSFPSP-XKBZYTNZSA-N 0.000 description 1
LZLREEUGSYITMX-JQWIXIFHSA-N Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-JQWIXIFHSA-N 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
201000002661 Spondylitis Diseases 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
206010072148 Stiff-Person syndrome Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
102000011362 Thioredoxin domains Human genes 0.000 description 1
108050001669 Thioredoxin domains Proteins 0.000 description 1
102100034769 Thioredoxin-dependent peroxide reductase, mitochondrial Human genes 0.000 description 1
DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102400000713 Thrombin light chain Human genes 0.000 description 1
101800001027 Thrombin light chain Proteins 0.000 description 1
108010046075 Thymosin Proteins 0.000 description 1
102000007501 Thymosin Human genes 0.000 description 1
102100029689 Thyroid hormone receptor-associated protein 3 Human genes 0.000 description 1
108050009589 Thyroid hormone receptor-associated protein 3 Proteins 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
102100026260 Titin Human genes 0.000 description 1
102300058373 Titin isoform 2 Human genes 0.000 description 1
102100031016 Transgelin-2 Human genes 0.000 description 1
108050006805 Transgelin-2 Proteins 0.000 description 1
102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 1
101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 1
108050000002 Tropomodulin-3 Proteins 0.000 description 1
102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 1
101710128188 Tropomyosin alpha-1 chain Proteins 0.000 description 1
102100033080 Tropomyosin alpha-3 chain Human genes 0.000 description 1
101710091952 Tropomyosin alpha-3 chain Proteins 0.000 description 1
UEFHVUQBYNRNQC-SFJXLCSZSA-N Trp-Phe-Thr Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=CC=C1 UEFHVUQBYNRNQC-SFJXLCSZSA-N 0.000 description 1
101710117197 Tubulin alpha-4A chain Proteins 0.000 description 1
102100025239 Tubulin alpha-4A chain Human genes 0.000 description 1
102100031904 Tumor protein D54 Human genes 0.000 description 1
101710190248 Tumor protein D54 Proteins 0.000 description 1
OHOVFPKXPZODHS-SJWGOKEGSA-N Tyr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OHOVFPKXPZODHS-SJWGOKEGSA-N 0.000 description 1
FASACHWGQBNSRO-ZEWNOJEFSA-N Tyr-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FASACHWGQBNSRO-ZEWNOJEFSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
DAVNYIUELQBTAP-XUXIUFHCSA-N Val-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N DAVNYIUELQBTAP-XUXIUFHCSA-N 0.000 description 1
ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
102000003970 Vinculin Human genes 0.000 description 1
108090000384 Vinculin Proteins 0.000 description 1
102300041335 Vinculin isoform 2 Human genes 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
229940119059 actemra Drugs 0.000 description 1
229940060201 actiq Drugs 0.000 description 1
230000004721 adaptive immunity Effects 0.000 description 1
239000000695 adrenergic alpha-agonist Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940060516 alferon n Drugs 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000000961 alloantigen Effects 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
229960004238 anakinra Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000012491 analyte Substances 0.000 description 1
108010091513 apolipoprotein B receptor Proteins 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229940094361 arcalyst Drugs 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
108010047857 aspartylglycine Proteins 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000000599 auto-anti-genic effect Effects 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
208000027625 autoimmune inner ear disease Diseases 0.000 description 1
230000010455 autoregulation Effects 0.000 description 1
230000001651 autotrophic effect Effects 0.000 description 1
229940054745 avinza Drugs 0.000 description 1
229940003504 avonex Drugs 0.000 description 1
RXQNHIDQIJXKTK-UHFFFAOYSA-N azane;pentanoic acid Chemical compound [NH4+].CCCCC([O-])=O RXQNHIDQIJXKTK-UHFFFAOYSA-N 0.000 description 1
229940055553 azficel-t Drugs 0.000 description 1
150000001541 aziridines Chemical class 0.000 description 1
DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical compound C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
229960000817 bazedoxifene Drugs 0.000 description 1
239000011324 bead Substances 0.000 description 1
150000008107 benzenesulfonic acids Chemical class 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000012965 benzophenone Substances 0.000 description 1
150000008366 benzophenones Chemical class 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
229940021459 betaseron Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000003766 bioinformatics method Methods 0.000 description 1
230000009141 biological interaction Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
239000012503 blood component Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical group [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
238000007623 carbamidomethylation reaction Methods 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
QSWSZIQYTSNSNR-UHFFFAOYSA-N carbon dioxide;hexane Chemical compound O=C=O.CCCCCC QSWSZIQYTSNSNR-UHFFFAOYSA-N 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
230000008568 cell cell communication Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
201000010002 cicatricial pemphigoid Diseases 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
229940088949 cinryze Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
108700005721 conestat alfa Proteins 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940038717 copaxone Drugs 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
201000003278 cryoglobulinemia Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
229960003537 desflurane Drugs 0.000 description 1
DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
125000004431 deuterium atom Chemical group 0.000 description 1
HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
229960004253 dexmedetomidine Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
229940099212 dilaudid Drugs 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229960004419 dimethyl fumarate Drugs 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
229960004845 drospirenone Drugs 0.000 description 1
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
229940099191 duragesic Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
229960001174 ecallantide Drugs 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000008029 eradication Effects 0.000 description 1
239000002329 esterase inhibitor Substances 0.000 description 1
229960003575 estradiol acetate Drugs 0.000 description 1
FHXBMXJMKMWVRG-SLHNCBLASA-N estradiol acetate Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)C)=CC=C3[C@H]21 FHXBMXJMKMWVRG-SLHNCBLASA-N 0.000 description 1
229960004766 estradiol valerate Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940081345 estropipate Drugs 0.000 description 1
HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
OKOHFSWRKRCHAD-UHFFFAOYSA-N ethane ethanesulfonic acid Chemical compound CC.CCS(O)(=O)=O OKOHFSWRKRCHAD-UHFFFAOYSA-N 0.000 description 1
HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
229940010443 exalgo Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000028023 exocytosis Effects 0.000 description 1
229940077362 extavia Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229950006455 fadolmidine Drugs 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000004578 fetal growth Effects 0.000 description 1
231100000562 fetal loss Toxicity 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229940050762 firazyr Drugs 0.000 description 1
238000007667 floating Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
238000011990 functional testing Methods 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000005350 fused silica glass Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229960004553 guanabenz Drugs 0.000 description 1
229960003602 guanethidine Drugs 0.000 description 1
ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
229960002048 guanfacine Drugs 0.000 description 1
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
229960001016 guanoxabenz Drugs 0.000 description 1
229920000591 gum Polymers 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000046699 human CD14 Human genes 0.000 description 1
102000055164 human HSP90AA2P Human genes 0.000 description 1
102000051251 human MPO Human genes 0.000 description 1
102000044507 human SERPING1 Human genes 0.000 description 1
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
229960000240 hydrocodone Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229960001410 hydromorphone Drugs 0.000 description 1
XHILEZUETWRSHC-NRGUFEMZSA-N hydromorphone hydrochloride Chemical compound [H+].[Cl-].O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XHILEZUETWRSHC-NRGUFEMZSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
229960001062 icatibant Drugs 0.000 description 1
108700023918 icatibant Proteins 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000008975 immunomodulatory function Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000266 injurious effect Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
108010010648 interferon alfacon-1 Proteins 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
238000005040 ion trap Methods 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
229940089053 kadian Drugs 0.000 description 1
229940018902 kalbitor Drugs 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
229940054136 kineret Drugs 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
238000002357 laparoscopic surgery Methods 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
239000008141 laxative Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
229960004942 lenalidomide Drugs 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
229960004400 levonorgestrel Drugs 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
238000002824 mRNA display Methods 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
229940107698 malachite green Drugs 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
229960002140 medetomidine Drugs 0.000 description 1
229960004616 medroxyprogesterone Drugs 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
230000005055 memory storage Effects 0.000 description 1
230000003821 menstrual periods Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229960003663 metaraminol Drugs 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
229960005192 methoxamine Drugs 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229960001207 micronized progesterone Drugs 0.000 description 1
229960001094 midodrine Drugs 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
108700007621 mifamurtide Proteins 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
210000001700 mitochondrial membrane Anatomy 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
229960005358 monensin Drugs 0.000 description 1
GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
125000005487 naphthalate group Chemical group 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
238000013188 needle biopsy Methods 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
125000006502 nitrobenzyl group Chemical group 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
229960001652 norethindrone acetate Drugs 0.000 description 1
229960000417 norgestimate Drugs 0.000 description 1
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
229940105606 oxycontin Drugs 0.000 description 1
229960001528 oxymetazoline Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000008775 paternal effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
238000003068 pathway analysis Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
108010027737 peginterferon beta-1a Proteins 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
229920009441 perflouroethylene propylene Polymers 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
108030002458 peroxiredoxin Proteins 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
229960005330 pimecrolimus Drugs 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000011505 plaster Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229940007060 plegridy Drugs 0.000 description 1
210000004910 pleural fluid Anatomy 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920005591 polysilicon Polymers 0.000 description 1
229920000131 polyvinylidene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
208000012113 pregnancy disease Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
210000005211 primary lymphoid organ Anatomy 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
208000019585 progressive encephalomyelitis with rigidity and myoclonus Diseases 0.000 description 1
108010042412 prolactin-inhibitory factor receptor Proteins 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
238000000751 protein extraction Methods 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000007388 punch biopsy Methods 0.000 description 1
230000001543 purgative effect Effects 0.000 description 1
229940117820 purinethol Drugs 0.000 description 1
229940069591 purixan Drugs 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000010833 quantitative mass spectrometry Methods 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000003660 reticulum Anatomy 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
238000002702 ribosome display Methods 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229960001886 rilonacept Drugs 0.000 description 1
108010046141 rilonacept Proteins 0.000 description 1
229940116747 roxicodone Drugs 0.000 description 1
239000005060 rubber Substances 0.000 description 1
229940009560 ruconest Drugs 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229960000953 salsalate Drugs 0.000 description 1
239000004576 sand Substances 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007790 scraping Methods 0.000 description 1
210000005212 secondary lymphoid organ Anatomy 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229960002078 sevoflurane Drugs 0.000 description 1
DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
229960003323 siltuximab Drugs 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229940126586 small molecule drug Drugs 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
NGIYLSFJGRLEMI-MHTUOZSYSA-M sodium 2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(2R,3R,4R,5R)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethyl [(2R)-2,3-di(hexadecanoyloxy)propyl] phosphate hydrate Chemical compound O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC NGIYLSFJGRLEMI-MHTUOZSYSA-M 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
229940100996 sodium bisulfate Drugs 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
229940001482 sodium sulfite Drugs 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000000551 statistical hypothesis test Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
238000006277 sulfonation reaction Methods 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229940053017 sylvant Drugs 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000012353 t test Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229940121136 tecfidera Drugs 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000011191 terminal modification Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
125000005505 thiomorpholino group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
229960000488 tizanidine Drugs 0.000 description 1
229960003989 tocilizumab Drugs 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
229960000401 tranexamic acid Drugs 0.000 description 1
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
238000001665 trituration Methods 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
229910052724 xenon Inorganic materials 0.000 description 1
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1